Synapse - A phase 2 study of minimal residual disease (MRD)-adapted front line venetoclax and obinutuzumab in fit patients with chronic lymphocytic leukemia (CLL): Effect of obinutuzumab on tumor lysis syndrome (TLS) risk and safety of outpatient venetoclax dose escalation

A phase 2 study of minimal residual disease (MRD)-adapted front line venetoclax and obinutuzumab in fit patients with chronic lymphocytic leukemia (CLL): Effect of obinutuzumab on tumor lysis syndrome (TLS) risk and safety of outpatient venetoclax dose escalation Meeting Abstract

Authors:	Roeker, L. E.; Zelenetz, A. D.; Park, J. H.; Derkach, A.; Geyer, M. B.; Islam, P.; Falchi, L.; Palomba, M. L.; Kumar, A.; Salles, G.; Lue, J. K.; Goldberg, A. D.; Fakhri, B.; Coombs, C. C.; Falco, V.; Panton, G.; Tyznar, D.; Soni, D.; Nogan, L.; Lebowitz, S.; Blesie, K.; Shah, M.; Court, S.; Jensen, C. E.; Mato, A. R.; Thompson, M. C.
Abstract Title:	A phase 2 study of minimal residual disease (MRD)-adapted front line venetoclax and obinutuzumab in fit patients with chronic lymphocytic leukemia (CLL): Effect of obinutuzumab on tumor lysis syndrome (TLS) risk and safety of outpatient venetoclax dose escalation
Meeting Title:	65th Annual Meeting of the American Society for Radiation Oncology (ASTRO 2023)
Journal Title:	Blood
Volume:	142
Issue:	Suppl. 1
Meeting Dates:	2023 Dec 9-12
Meeting Location:	San Deigo, CA
ISSN:	0006-4971
Publisher:	American Society of Hematology
Date Published:	2023-11-02
Start Page:	4657
Language:	English
ACCESSION:	WOS:001159740308146
DOI:	10.1182/blood-2023-181661
PROVIDER:	wos
Notes:	Meeting Abstract -- Source: Wos